Mesothelioma: the key unanswered question
Durvalumab: the new standard of care for NSCLC?
Changes in tumour biomarkers after neoadjuvant chemotherapy in breast cancer
ESMO 2016: Press brief on the AFFINITY Phase III trial for second-line metastatic prostate cancer
Anamorelin for cachexia for patients with NSCLC